logo

Against Monopoly

defending the right to innovate

Monopoly corrupts. Absolute monopoly corrupts absolutely.





Copyright Notice: We don't think much of copyright, so you can do what you want with the content on this blog. Of course we are hungry for publicity, so we would be pleased if you avoided plagiarism and gave us credit for what we have written. We encourage you not to impose copyright restrictions on your "derivative" works, but we won't try to stop you. For the legally or statist minded, you can consider yourself subject to a Creative Commons Attribution License.


current posts | more recent posts | earlier posts

Patent Attorneys Prove To Be Too Big A Lobby For Even The Most Modest Of Reforms

Behold the latest proof -

Patent lawyers started breathing again Wednesday, as the specter of new patent rules was chased away -- at least for a little while -- by a Virginia court.

U.S. District Judge James Cacheris granted pharmaceutical giant GlaxoSmithKline's motion for a preliminary injunction blocking the U.S. Patent and Trademark Office from implementing rules set to go into effect today.

The new rules would reduce the number of claims, which help define a patent, and the number of continuations, which are used to amend patent claims and contest those that are rejected. Claims would be limited to 25, and continuations to just three. The current rules imposed no limits.

"I won't be alone in being among the patent attorneys who are very pleased with the injunction that was granted today," said Neil Smith, a veteran IP lawyer at Sheppard, Mullin, Richter & Hampton in San Francisco. "Anyone who cares about the strength of patents and about innovation itself saw those rules as causing some real problems -- it's a good day for the patent system."

The patent office says the rule changes are meant to speed up the patent process and eliminate the enormous backlog of applications. But opponents say the changes could weaken patents by not allowing sufficient continuances to cover ever-evolving innovations. They also say the new rules would have unfairly been retroactive on pending applications.

Notice how patent attorneys engage in Orewllian Newspeak talking about the "strength of patents" and "innovation". Always have to read between the lines with them - much like politicians.

Read the whole article here.

Just When You Thought The Patent System Couldn't Become A Bigger Farce Than It Already Is...

Via Techdirt -

"Welcome to the lovely world of patent extortion, where the money from the practice is so lucrative that one of the highest paid lawyers at a top law firm would quietly license his patents to be used against his own firm's clients in exchange for a cut of the profits."

You have to read it to believe it.

Bring the suit in a virtual court having jurisdiction

Here is another IP as a Joke item. Nate Anderson reports that a player in the virtual world game Second Life had "her Nomine-branded avatar skins allegedly ripped off by another user who has been selling counterfeit copies for his own profit." She has now gone to court for violation of her copyright link here. Since the skins can be sold to others for "virtual" Linden dollars, for which there is a real-world dollar market among other game players, the skins can be said to have some value, but only among the demented.

For more on the case, read this link here

It will be interesting to see where the court takes it, in another example of the unreality of IP law. Why not set up avatars of lawyers and a court and a judge and a Congress to revise the law? Then the real-world judge could argue that he does not have jurisdiction and the suit has been brought in the wrong court. Problem solved.

Can Systems Biology Reduce the Cost of Pharmaceutical Innovation?

Systems biology--the use of software models that produce outputs acting like living organisms--holds great promise for the pharmaceutical industry. Four drug firms are part of a group using it to learn the effect of new drugs on the heart.

The prospect is that this approach can speed up the drug testing process. A British firm, e-Therapeutics, says it can test the effects of a new compound in two weeks, compared to the usual two years.

Testing can go beyond this though, to assay alternative therapies, such as herbs and clinical nutrition, and possibly to determine the causes of diseases caused by genetic and environmental factors.

Here is the article, "All Systems Go", from The Economist.

The Pharmaceutical Industry's Search for a New Business Model

After WW II the proprietary drug industry developed a blockbuster model supported by the patent system. Global markets and monopoly rents fueled these firms' stock prices for years, despite the growth of generic competition. But its model is becoming unglued. As blockbusters come off patent, the revenues and earnings from these drugs are becoming more difficult to replace. Some drugs have failed and have been scrapped. Pfizer's recent decision to scrap its hoped-for insulin inhaler blockbuster Exubera after investing more than $2 billion developing it was unprecedented, according to the Wall Street Journal. The patent system itself is under political and legal pressure.

So now these firms are going back to the drawing board and seeking ways to innovate their way out of the mess. Outsourcing, long the bane of the industry, is coming into vogue. Marketing is also being rethought. Big pharma spends one-third or more of its revenues in the U.S. on marketing compared with less than a fifth on R&D. Are sales reps and ad agencies really that innovative?

In addition to changing their R&D focus to encompass personalized medicine and other innovative techniques, proprietary firms are diversifying into generics, diagnostics, biotechnology, and other areas. In diversifying their portfolios, they are hedging their risks, but also increasing their chances of finding new innovations and markets.

Call it the Goldman Sachs model. That firm has prospered by having a good management team, by innovating, and by venturing into new markets. If one market get into trouble, it's so diversified and well managed that it can keep chugging along, innovating as it goes.

The Economist reports in "Beyond the Pill".

Comcast caught restricting broadband users

Comcast has come under criticism, first for having slowed its broadband users' large file transfers in apparent disregard of their service contracts and more recently for lying about it link here. They seem now to have been caught. They were not the ones restricting usage, but they had hired another company to do it for them link here. In judging this, one needs to remember that Comcast is at best a duopolist in markets with few or no other companies offering broadband .

The one positive fallout of this is that it has revived the campaign for legally enforcing net neutrality. Consumers are simply not sure that they can get a fair shake from competition in these markets.

Copyright discrimination?

Fair use is now an issue in the Republican nomination race link here. John McCain used several seconds of Fox News video of a campaign debate in one of his ads which should be all right under fair use, but he has been told to take it down for copyright violation. But two other candidates using similar footage have not been so treated. Where is the fair in this use? Does a copyright owner have the right to enforce it discriminatorily? Get me a lawyer. Better, get rid of copyright.

Six ideas for copyright reform

Gigi Sohn proposes six points to reform copyright in a speech yesterday link here. The complete text is available here. Teeing off from the fact that the scope and duration of copyright has been steadily expanded, limiting innovation, she suggests fair use changes, limits on secondary liability, protection against copyright abuse, better licensing, orphan works reform, and better notification of technological and contractual restrictions on digital media. Most of our readers would prefer abolition of copyright but it isn't going to happen any time soon, so these ideas are worth a lot of discussion.

Patent Litigation

Interesting paper by Hall and Ziedonis: my summary - firms can produce products or patent litigation, but not both. From a social point of view, it might be better if they focused on the former.

One Click

Stephen Spear previously posted on the invalidation of (most of the claims of) the infamous one-click patent. Credit goes to Peter Calveley, whose effort we previously mentioned (and I at least contributed to) here. Mainly though this flies in the face of what I was told was the "conventional wisdom among experts" that in fact this was a good patent.

current posts | more recent posts | earlier posts


   

Most Recent Comments

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Sheldon Richman on Intellectual Property versus Liberty test

Pimps and Ferrets: Copyright and Culture in the United States, 1831-1891 test

Pimps and Ferrets: Copyright and Culture in the United States, 1831-1891 test

Pimps and Ferrets: Copyright and Culture in the United States, 1831-1891 test